KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Net Income towards Common Stockholders: 2009-2025

Historic Net Income towards Common Stockholders for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to $175.2 million.

  • Halozyme Therapeutics' Net Income towards Common Stockholders rose 27.89% to $175.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $595.5 million, marking a year-over-year increase of 51.72%. This contributed to the annual value of $444.1 million for FY2024, which is 57.71% up from last year.
  • As of Q3 2025, Halozyme Therapeutics' Net Income towards Common Stockholders stood at $175.2 million, which was up 6.11% from $165.1 million recorded in Q2 2025.
  • Halozyme Therapeutics' 5-year Net Income towards Common Stockholders high stood at $216.6 million for Q3 2021, and its period low was $22.7 million during Q2 2022.
  • Over the past 3 years, Halozyme Therapeutics' median Net Income towards Common Stockholders value was $93.2 million (recorded in 2024), while the average stood at $107.6 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first spiked by 557.07% in 2021, then slumped by 75.20% in 2022.
  • Over the past 5 years, Halozyme Therapeutics' Net Income towards Common Stockholders (Quarterly) stood at $66.8 million in 2021, then declined by 13.58% to $57.7 million in 2022, then skyrocketed by 47.98% to $85.4 million in 2023, then surged by 60.46% to $137.0 million in 2024, then climbed by 27.89% to $175.2 million in 2025.
  • Its Net Income towards Common Stockholders was $175.2 million in Q3 2025, compared to $165.1 million in Q2 2025 and $118.1 million in Q1 2025.